Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Iclusig
Ponatinib is a tyrosine kinase inhibitor (TKI) used to treat certain types of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It works by blocking specific proteins that promote cancer cell growth. Ponatinib is generally reserved for patients who are resistant or intolerant to other TKIs.
For the treatment of certain types of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to other TKIs.
Ponatinib carries a risk of serious arterial and venous thrombotic and occlusive events, including fatal myocardial infarction, stroke, and hepatic artery occlusion. It also has the potential to cause severe hepatotoxicity. Monitor patients closely for vascular and hepatic adverse events.
Outcome:
Reduced ponatinib effectiveness
Mechanism:
Induction of CYP3A4
Outcome:
Reduced ponatinib absorption
Mechanism:
Chelation/pH changes
Outcome:
Increased ponatinib absorption
Mechanism:
Enhanced solubility
Most likely new formulation: Combination therapy with other targeted agents (Year: 2025, 70% confidence)
Based on current usage and safety profile, there is a low (<5%) likelihood of regulatory restrictions in the next 2 years.
Tyrosine Kinase Inhibitor (TKI)
Thienopyrimidine